EUVIMEDEUVIMED entdecken
Crossref

Low-Dose Valganciclovir Prophylaxis Against Cytomegalovirus in Intermediate-Risk Liver and Dual-Abdominal Transplant Recipients

Yihan Li iD, Dawn M Pluckrose, Roshani Patolia, Serena Arnouk, Yanina Dubrovskaya, John Papadopoulos, Srijana Jonchhe

Annals of Pharmacotherapy · 2025

DOI: 10.1177/10600280241255110 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Pharmacotherapy, 2025. Verfasst von Yihan Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, NYU Langone Health, New York, NY, USA. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Valganciclovir, Liver Transplantation, Antiviral Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Low-dose valganciclovir (VGC) for cytomegalovirus (CMV) prophylaxis post-transplant has been employed due to cost and safety. The incidence of CMV disease in CMV intermediate-risk liver recipients at 1-year after standard-dose prophylaxis is approximately 5%. However, there are limited data on outcomes after using a “true” low-dose VGC prophylaxis regimen in liver and dual-abdominal transplant recipients as VGC was not dose-adjusted in all patients with impaired renal function in prior studies.

Objective

The objective was to assess the incidence of CMV associated with low-dose VGC prophylaxis in CMV intermediate-risk liver, simultaneous pancreas-kidney (SPK), and simultaneous liver-kidney (SLK) recipients with creatinine clearance (CrCl) >60 mL/min.

Methods

This was a retrospective review of CMV intermediate-risk liver, SPK, and SLK recipients with CrCl >60 mL/min transplanted January 2018 to June 2022 who received VGC 450 mg daily for prophylaxis. The primary outcome was incidence of CMV infection 6-months post-transplant.

Results

Ninety-nine transplant recipients were included (79 liver, 11 SPK, 9 SLK). The primary outcome occurred in 13% of patients (liver 10%, SPK 36%, SLK 10%), including 1 case of CMV disease and 3 breakthrough infections. In addition, 6 patients experienced CMV infection between 6-months and 1-year. Recurrence occurred in 3 patients. There was no evidence of CMV resistance. Thirty patients experienced neutropenia within 1-year, 32 were prescribed granulocyte-colony stimulating factors, and 5 experienced thrombocytopenia. Two patients died due to graft-vs-host disease. Conclusion and Relevance: Low-dose VGC prophylaxis led to comparable CMV infection rates at 6-months in CMV intermediate-risk liver and SLK recipients. However, as SPK recipients displayed higher rates of CMV infection, low-dose VGC should be avoided in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytomegalovirus InfectionsValganciclovirLiver TransplantationAntiviral AgentsHumansMaleMiddle AgedFemaleRetrospective StudiesAdultKidney TransplantationAgedCytomegalovirusPancreas TransplantationIncidenceTransplant Recipients

Stichwörter der Autor:innen

cytomegalovirusliver transplantationlow-dose valganciclovirsimultaneous liver-kidney transplantationsimultaneous pancreas-kidney transplantation

Substanzen

ValganciclovirAntiviral Agents

Autor:innen und Institutionen

  • Department of Pharmacy, NYU Langone Health, New York, NY, USA.
  • Department of Pharmacy, Tufts Medical Center, Boston, MA, USA.

ORCID-Profile: Yihan Li

Zitieren

APA

Li, Y., Pluckrose, D. M., Patolia, R., Arnouk, S., Dubrovskaya, Y., Papadopoulos, J., & Jonchhe, S. (2025). Low-Dose Valganciclovir Prophylaxis Against Cytomegalovirus in Intermediate-Risk Liver and Dual-Abdominal Transplant Recipients. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280241255110

Vancouver

Li Y, Pluckrose DM, Patolia R, Arnouk S, Dubrovskaya Y, Papadopoulos J, et al. Low-Dose Valganciclovir Prophylaxis Against Cytomegalovirus in Intermediate-Risk Liver and Dual-Abdominal Transplant Recipients. Annals of Pharmacotherapy. 2025. doi:10.1177/10600280241255110

BibTeX
@article{Li2025,
  author = {Li, Yihan and Pluckrose, Dawn M and Patolia, Roshani and Arnouk, Serena and Dubrovskaya, Yanina and Papadopoulos, John and Jonchhe, Srijana},
  title = {Low-Dose Valganciclovir Prophylaxis Against Cytomegalovirus in Intermediate-Risk Liver and Dual-Abdominal Transplant Recipients},
  journal = {Annals of Pharmacotherapy},
  year = {2025},
  doi = {10.1177/10600280241255110}
}
Kostenlos starten →